AVXL SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

News

TYPE

HEADLINE

FILED AT

8-K

Anavex Life Sciences Appoints Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer

Nov 3, 2026

8-K

Anavex Life Sciences Corp. Announces Resignation of Three Board Members and Reconstitution of Board Committees

Nov 2, 2026

8-K

Anavex Completes Clinical Conduct of ADME and DDI Studies and Provides Corporate Pipeline Update

Oct 20, 2026

8-K

Anavex Receives FDA Clearance of IND Application for Blarcamesine in Fragile X Syndrome

Oct 15, 2026

8-K

Anavex Life Sciences Reports Voting Results from 2026 Annual Meeting and Board Change Control Trigger

Sep 28, 2026

8-K

Anavex Life Sciences Granted FDA Meeting to Discuss Pediatric Patients in Rett Syndrome Phase 3 Clinical Trial

Sep 9, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

July ATM | Offering amount: $150,000,000

Jul 25, 2025

424B5

SHELF OFFERING | Share price: $11.26 | Offering amount: $150,000,000.00

Feb 7, 2023

424B5

SHELF OFFERING | Shares amount: 2,380,953 | Share price: $21.00 | Offering amount: $50,000,013.00

Jun 24, 2021

424B5

$250,000,000 of Common Stock-

Feb 16, 2021

424B5

$250,000,000 of Common Stock

Jul 2, 2020

424B5

$250,000,000 of Common Stock

May 1, 2020

Registrations

TYPE

HEADLINE

FILED AT

S-3

July 2025 SHELF

Jul 14, 2025

S-3

SHELF | Offering amount: $150,000,000.00

Jul 29, 2024

S-8

Registration

Jun 10, 2022

S-3ASR

Common Stock-

Sep 24, 2021

S-8

6,000,000 (2)

Apr 9, 2021

POS AM

Registration

Sep 17, 2019

Proxies

TYPE

HEADLINE

FILED AT

DFAN14A

Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material

Sep 18, 2026

DFAN14A

Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material

Sep 18, 2026

DFAN14A

Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material

Sep 17, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Sep 15, 2026

DFAN14A

Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material

Sep 15, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Sep 14, 2026

Ownerships

TYPE

HEADLINE

FILED AT

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 24, 2025

CORRESP

Form CORRESP - Correspondence

Jul 21, 2025

LETTER

Form UPLOAD - SEC-generated letter

Jul 21, 2025

LETTER

Form UPLOAD - SEC-generated letter

Aug 12, 2022

CORRESP

Form CORRESP - Correspondence

Aug 10, 2022

LETTER

Form UPLOAD - SEC-generated letter

Jul 29, 2022

Anavex Life Sciences Corp. AVXL · SEC Filings